- This event has passed.
22/10/2020 – Failed it to Nailed it! How to get data sharing right! – Dealing with Data: Tips & Tricks
22nd October 2020 @ 1:30 pm - 4:50 pmFree
**This event has now passed, click here for event coverage**
Eventbrite Link: https://fi2ni-datasharing-221020.eventbrite.co.uk
This event forms part of the ‘Failed it to Nailed it – Getting Data Sharing Right’ series. This series is run by the Artificial Intelligence for Scientific Discovery Network+ (AI3SD), the Cell Press Patterns Journal and the Physical Sciences Data-Science Service (PSDS). These events are a product of the data sharing survey we ran earlier this year.
This event is the first of four events in our ‘Failed it to Nailed it – Getting Data Sharing Right’ series. This event aims to provide general advice on a range of aspects of research data management including handling and sharing data. We have three talks by experts in research data management and data wrangling. The event will also feature a panel comprised of Early Career Researchers who will each provide their top tips for handling data, and reflect on the lessons they have learned about data throughout their career so far.
- 13:30-13:45 – Introductions & Coffee
- 13:45-14:15 – Love notes to the future: the importance of metadata (Ms Isobel Stark – University of Southampton)
- 14:15-14:45 – Pitfalls and Gotcha’s with bioactivity data (Professor John Overington – Medicines Discovery Catapult)
- 14:45-15:10 – Coffee Break
- 15:10-15:40 – Digitising your Chemistry for Recordability, Shareabilty and Reproducibility (Dr Mark Warne – Deep Matter)
- 15:40-16:40 – ECR Panel discussion
- 16:40-16:50 – Wrap up and close
Ms Isobel Stark – University of Southampton: Isobel Stark is the University’s Research Data Development Manager. Isobel has worked in academic libraries since graduating with an MA in Librarianship from the University of Sheffield in 1994. In that time both libraries and how users access information have changed considerably. Isobel works in partnership with other university services and researchers to ensure that research outputs are effectively captured, recorded, stored and shared, maximising the exposure of research to public and academic audiences. In addition as part of the Library Research Engagement team she is available to help with Open Access, Data Management, Measuring Impact (Bibliometrics) Systematic Reviews, Theses and other research related matters.
Professor John Overington – Medicines Discovery Catapult: John Overington holds a first degree in chemistry and studied for his PhD on comparative protein modelling, drug design, and sequence-structure relationships with Sir Tom Blundell at Birkbeck College, London. After a postdoctoral fellowship with the Imperial Cancer Research Fund, London, he joined Pfizer Central Research in the United Kingdom and eventually became manager of the Molecular Informatics, Structure and Design Department, where he was responsible for cheminformatics, structural biology, target analysis, and molecular modelling. He joined Inpharmatica in 2000; Inpharmatica was acquired by Galapagos NV in December 2006. There he was Senior Director, Discovery Informatics of the Galapagos subsidiary BioFocus DPI. In October 2008 he was appointed Team Leader, Chemogenomics at the European Molecular Biology Laboratory (EMBL), working at the European Bioinformatics Institute (EMBL-EBI) in Hinxton, U.K. where he established and ran the ChEMBL group. Following that, he spent two years as VP Biomedical Informatics at BenevolentAI. He became Chief Informatics Officer at Medicines Discovery Catapult (MDC) in 2017.
Dr Mark Warne – Deep Matter: Mark Warne, was appointed as Chief Executive Officer of DeepMatter Group plc on the 2 July 2018. Mark, who joined DeepMatter as a Non-Executive Director in September 2015 also served as its Executive Chairman between April 2017 and July 2018. Mark is widely recognised in the UK and International life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. He managed a portfolio of £330m of net assets in 2016/2017 and represented IP Group on the boards of both listed and private companies. In 2018, concurrent with the integration of Touchstone Innovations into IP Group, Mark became a Partner in the Life Sciences division. He joined IP Group from pre-clinical drug discovery CRO, Exelgen, where he was Managing Director. Mark spent eight years at Exelgen (formerly Tripos Discovery Research) where he also held positions in licensing and strategic affairs, project management and research. He has a PhD in Computational Chemistry, an MSc in Colloid Science and a BSc in Chemistry, all from the University of Bristol. Mark is a Chartered Chemist and member of the Royal Society of Chemistry. He serves as a non-executive director on the boards of Open Orphan plc and Ixico plc.